melanoma
Oncology · 2011–2023
46decisions
15medicines
27carried consumer input
810individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| relatlimab and nivolumab Treatment of patients with unresectable Stage III or IV malignant melanoma who are previously untreated with a PD-1 inhibitor for this indication. | Jul 2023 | Recommended with restriction | input received Rare Cancers Australia · Medical Oncology Group |
| relatlimab with nivolumab Treatment of patients with unresectable Stage III or IV malignant melanoma who have not previously been treated with a PD-1 inhibitor for this indication. | Jul 2022 | Not recommended | 6 individuals Skin Cancer Advocacy Network · Melanoma Patients Australia · Medical Oncology Group |
| nivolumab and ipilimumab Treatment of unresectable Stage III or IV malignant melanoma in patients who experience melanoma recurrence while receiving or within 6 months of completing… | Nov 2022 | Recommended with restriction | 1 individuals |
| pembrolizumab Addition of a 400 mg every six weeks flat dosing regimen to the existing 200 mg every three weeks flat dosing regimen for unresectable Stage III or Stage IV… | Mar 2020 | Recommended | 2 individuals Lung Foundation Australia |
| pembrolizumab First-line treatment of unresectable Stage III or Stage IV metastatic malignant melanoma in patients with a BRAF V600 mutation who have not received prior… | Mar 2020 | Recommended | input received Medical Oncology Group |
| pembrolizumab Adjuvant treatment of patients with resected Stage IIIB, IIIC or IIID malignant melanoma. | Mar 2020 | Recommended | input received Medical Oncology Group |
| dabrafenib + trametinib Adjuvant treatment of patients with BRAF V600 mutation positive resected Stage IIIB, IIIC or IIID melanoma following complete surgical resection. | Jul 2019 | Recommended with restriction | 3 individuals Melanoma Patients Australia · Australian Melanoma Consumer Alliance · Melanoma Research Victoria Consumer Reference Group · Medical Oncology Group |
| nivolumab Adjuvant treatment of patients with completely resected Stage IIIB, IIIC, IIID or Stage IV melanoma. | Jul 2019 | Deferred | 18 individuals Melanoma Patients Australia · Australian Melanoma Consumer Alliance · Melanoma Research Victoria Consumer Reference Group · Medical Oncology Group |
| pembrolizumab Adjuvant treatment of patients with completely resected Stage IIIB, IIIC or IIID malignant melanoma at high risk of recurrent disease. | Jul 2019 | Not recommended | 2 individuals Melanoma Patients Australia · Australian Melanoma Consumer Alliance · Melanoma Research Victoria Consumer Reference Group · Medical Oncology Group |
| dabrafenib and trametinib Adjuvant treatment of patients with BRAF V600 mutation positive melanoma with completely resected Stage III disease (specifically Stage IIIB, IIIC, and IIID). | Mar 2019 | Deferred | input received |
| nivolumab Adjuvant treatment for completely resected Stage III or IV melanoma. | Mar 2019 | Not recommended | 67 individuals Melanoma Patients Australia · Medical Oncology Group |
| nivolumab Addition of flat dosing regimens (240 mg Q2W and 480 mg Q4W) to existing weight-based dosing for multiple PBS-listed indications including unresectable Stage… | Mar 2019 | Recommended with restriction | unclear |
| nivolumab First-line treatment of unresectable Stage III or Stage IV malignant melanoma with BRAF V600 mutation, as monotherapy or in combination with ipilimumab. | Nov 2019 | Recommended with restriction | 21 individuals Melanoma Patients Australia · Australian Melanoma Consumer Alliance · Melanoma Research Victoria Consumer Reference Group |
| nivolumab Adjuvant treatment of completely resected Stage IIIB, IIIC, IIID or Stage IV malignant melanoma. | Nov 2019 | Recommended with restriction | none received |
| pembrolizumab Adjuvant treatment of patients with completely resected Stage IIIB, IIIC, and IIID malignant melanoma. | Nov 2019 | Recommended with restriction | 3 individuals Melanoma Patients Australia · Medical Oncology Group |
| nivolumab and ipilimumab Treatment of unresectable Stage III or Stage IV malignant melanoma, as first-line immunotherapy in patients with BRAF V600 mutation negative melanoma, and… | Jul 2018 | Recommended with restriction | 310 individuals |
| nivolumab Adjuvant treatment for completely resected Stage III or Stage IV melanoma. Nivolumab 3 mg/kg administered as an intravenous infusion over 60 minutes every 2… | Jul 2018 | Not recommended | 40 individuals Melanoma Patients Australia · Cancer Council Australia · Medical Oncology Group |
| pembrolizumab Unresectable Stage III or Stage IV malignant melanoma. This is a minor submission requesting a change from weight-based dosing (2 mg/kg) to fixed 200 mg dosing. | Mar 2018 | Recommended with restriction | unclear |
| encorafenib; binimetinib Treatment of unresectable or metastatic melanoma with a BRAF V600 mutation in adult patients. | Nov 2018 | Recommended with restriction | 6 individuals Melanoma Institute · Cancer Council Australia |
| pembrolizumab Adjuvant treatment for completely resected Stage III malignant melanoma. | Nov 2018 | Not recommended | 19 individuals |
| pembrolizumab Treatment of unresectable Stage III or Stage IV malignant melanoma. Includes two treatment phases: initial treatment for BRAF V600 mutation-positive patients… | Nov 2018 | Recommended with restriction | no section in document |
| nivolumab + ipilimumab Treatment of unresectable Stage III or Stage IV malignant melanoma. | Mar 2017 | Not recommended | 1 individuals Australian Melanoma Consumer Alliance · Melanoma Patients Australia · Medical Oncology Group |
| ipilimumab Treatment of unresectable stage III or stage IV malignant melanoma as monotherapy or as the sole PBS-subsidised therapy. | Jul 2016 | Recommended with restriction | input received |
| talimogene laherparepvec Treatment of unresectable stage III or stage IV malignant melanoma without visceral metastases (stage IIIb/c and stage IVM1a). | Jul 2016 | Not recommended | input received Melanoma Patients Australia |
| trametinib Treatment of patients with BRAF V600 mutation positive unresectable stage III or metastatic (stage IV) malignant melanoma, in combination with dabrafenib. | Jul 2016 | Recommended with restriction | none received |
| vemurafenib + cobimetinib Treatment of BRAF V600 mutation positive unresectable or metastatic melanoma as first-line therapy. | Mar 2016 | Recommended with restriction | none received |
| pembrolizumab Treatment of unresectable Stage III or Stage IV metastatic melanoma. The submission sought reconsideration of cost-effectiveness under a Managed Entry Scheme. | Mar 2016 | Not recommended | none received |
| pembrolizumab Treatment of unresectable Stage III or Stage IV malignant melanoma. The 100 mg concentrated injection is an alternative formulation to the currently listed 50… | Nov 2016 | Recommended with restriction | input received |
| pembrolizumab Monotherapy treatment of unresectable or metastatic melanoma in adults, specifically for patients who are BRAF mutation negative (first-line) or BRAF mutation… | Nov 2016 | Not recommended | input received Melanoma Patients Australia |
| ipilimumab Treatment of unresectable stage III or stage IV malignant melanoma. This document addresses the incidence and costs of treating adverse events (particularly… | Jul 2015 | Noted | no section in document |
| nivolumab Treatment of unresectable Stage III or Stage IV malignant melanoma, in patients with BRAF V600 wild-type mutation (first-line) or BRAF V600 mutant patients who… | Jul 2015 | Recommended with restriction | 12 individuals |
| pembrolizumab Treatment of unresectable Stage III or Stage IV metastatic melanoma in patients negative for BRAF V600 mutation (first-line, ipilimumab-naïve) or positive for… | Mar 2015 | Recommended with restriction | 275 individuals Australian Melanoma Consumer Alliance · Melanoma Patients Australia · CanSpeak Australia |
| dabrafenib and trametinib Treatment of BRAF-mutated type unresectable stage III or stage IV malignant melanoma. | Nov 2015 | Recommended with restriction | none received |
| nivolumab Treatment of unresectable Stage III or Stage IV malignant melanoma in combination with ipilimumab. | Nov 2015 | Not recommended | 24 individuals |
| nivolumab Treatment of unresectable Stage III or Stage IV malignant melanoma in previously untreated patients (BRAF wild-type) and in patients who have progressed on or… | Nov 2015 | Recommended with restriction | input received |
| trametinib Treatment of patients with BRAF V600 mutation positive unresectable stage III or metastatic (stage IV) melanoma in combination with dabrafenib. | Mar 2014 | Not recommended | input received Medical Oncology Group |
| trametinib Treatment of patients with BRAF V600 mutation positive unresectable stage III or metastatic (stage IV) melanoma, used in combination with dabrafenib. | Nov 2014 | Recommended with restriction | unclear |
| dabrafenib Treatment of patients with BRAF V600 mutation positive unresectable Stage III or metastatic (Stage IV) melanoma. | Jul 2013 | Recommended | no section in document |
| dabrafenib Treatment of patients with BRAF V600 mutation positive advanced (unresectable stage III) or metastatic (stage IV) melanoma. | Mar 2013 | Deferred | no section in document |
| vemurafenib Treatment of BRAF V600 mutation-positive patients with unresectable (stage IIIC) or metastatic (stage IV) melanoma with WHO performance status ≤2. | Mar 2013 | Recommended | no section in document |
| vemurafenib Treatment of previously untreated unresectable stage IIIC or stage IV melanoma positive for the BRAF V600 mutation. | Jul 2012 | Deferred | unclear |
| vemurafenib Treatment of previously untreated unresectable stage IIIC or stage IV metastatic melanoma positive for the BRAF V600 mutation. | Jul 2012 | Deferred | unclear |
| ipilimumab Treatment of patients with unresectable stage III or stage IV malignant melanoma who have not responded to or were intolerant to prior systemic therapy for… | Mar 2012 | Not recommended | unclear |
| ipilimumab Treatment of patients with unresectable stage III or stage IV malignant melanoma who have not responded to or were intolerant to prior systemic therapy for… | Mar 2012 | Not recommended | unclear |
| ipilimumab Treatment of patients with unresectable stage III or stage IV malignant melanoma who have not responded to or were intolerant to prior systemic therapy for… | Nov 2012 | Recommended with restriction | unclear |
| ipilimumab Treatment of patients with unresectable stage III or stage IV malignant melanoma who have not responded to or were intolerant to prior systemic therapy for… | Jul 2011 | Not recommended | unclear |
Who spoke
Melanoma Patients Australia · Medical Oncology Group · Australian Melanoma Consumer Alliance · Melanoma Research Victoria Consumer Reference Group · Cancer Council Australia · Melanoma Institute · Lung Foundation Australia · CanSpeak Australia · Rare Cancers Australia · Skin Cancer Advocacy Network
What the PBS pays
$1,865M in government benefit over 2024–25, across 177,700 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pembrolizumab | $739.6M |
| nivolumab + ipilimumab | $199M |
| nivolumab and ipilimumab | $199M |
| Ipilimumab | $113.8M |
| ipilimumab | $113.8M |
| nivolumab | $85.2M |
| relatlimab and nivolumab | $85.2M |
| relatlimab with nivolumab | $85.2M |
| encorafenib; binimetinib | $68.5M |
| dabrafenib + trametinib | $57.2M |
| dabrafenib and trametinib | $57.2M |
| trametinib | $29.4M |
Appraised elsewhere
NICE, in England and Wales, has appraised 18 technologies for this condition, recommending 16 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| nivolumabNivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal) | TA980 | terminated | 2024-06 |
| nivolumab relatlimabNivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over | TA950 | recommended restricted | 2024-02 |
| pembrolizumabPembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma | TA837 | recommended restricted | 2022-10 |
| pembrolizumabPembrolizumab for adjuvant treatment of completely resected stage 3 melanoma | TA766 | recommended restricted | 2022-02 |
| nivolumabNivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease | TA684 | recommended restricted | 2021-03 |
| encorafenibEncorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma | TA562 | recommended restricted | 2019-02 |
| dabrafenibDabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma | TA544 | recommended restricted | 2018-10 |
| cobimetinibCobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma | TA414 | not recommended | 2016-10 |
| talimogene laherparepvecTalimogene laherparepvec for treating unresectable metastatic melanoma | TA410 | recommended restricted | 2016-09 |
| nivolumabNivolumab in combination with ipilimumab for treating advanced melanoma | TA400 | recommended | 2016-07 |
| trametinibTrametinib in combination with dabrafenib for treating unresectable or metastatic melanoma | TA396 | recommended | 2016-06 |
| nivolumabNivolumab for treating advanced (unresectable or metastatic) melanoma | TA384 | recommended | 2016-02 |
Showing the 12 most recent of 18.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 27 of 37 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.